Emphymab Biotech is developing a first disease-modifying drug for emphysema and other chronic diseases
Emphymab is developing the first disease-modifying therapy that halts emphysema progression. Emphymab has developed a therapeutic antibody that neutralizes a inflammatory cytokine EMAPII that is enhanced in patients blocking lung destruction. After establishing proof-of-concept in clinical trials Emphymab will partner with a biopharma company. Emphymab has received a second Phases I SBIR and foundational support from the Harrington Institute.